Clinical Trial Update: Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating eight weeks of elbasvir/grazoprevir for chronic hepatitis C genotype 4 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)

Snippet

Sponsor: King Fahad Medical City | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED